Global Metronidazole Benzoate Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Capsules, Suspensions, Tablets, and Others), By Applications (Antiprotozoal, Antibacterial, and Others), By Distribution Channel (Clinics, Online Pharmacies, Hospitals, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Metronidazole Benzoate Market Insights Forecasts to 2033

• The Global Metronidazole Benzoate Market Size was estimated at USD 1.06 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 6.12% from 2023 to 2033
• The Worldwide Metronidazole Benzoate Market Size is expected to reach USD 1.92 Billion By 2033
• Asia Pacific is predicted to Grow at the Fastest CAGR throughout the projection period

The Global Metronidazole Benzoate Market Size is anticipated to exceed USD 1.92 billion by 2033, growing at a CAGR of 6.12% from 2023 to 2033.

Market Overview

The metronidazole benzoate market involves the production and distribution of metronidazole benzoate medications, a pharmaceutical drug used to treat bacterial and protozoal infections. Metronidazole benzoate is a benzoate ester formed by combining benzoic acid with metronidazole's hydroxy group. It serves as an antibacterial, antimicrobial, antiparasitic, antitrichomonal, and prodrug and is functionally related to metronidazole and benzoic acid. In the nitroimidazole class, metronidazole is a commonly used antibiotic that is used to treat trichomoniasis, parasites, and gastrointestinal diseases. It differs from other antibacterial medications in that it has antiparasitic effects. It is used to treat infections caused by Bacteroides species, Clostridium, Fusobacterium, Peptococcus, and Peptostreptococcus. It is available in capsule, tablet, and topical forms. Additionally, inflammatory rosacea lesions are treated with topical preparations. As a result of its unique characteristics, metronidazole is a therapy choice that can be used in numerous applications. The marketed products of metronidazole are Mnida, metrogyl, Flagyl, and Oflanex-MS suspensions, etc.

The rising prevalence of parasitic infections such as protozoal and amebiasis is escalating the need for metronidazole and its derivative metronidazole benzoate, which propels the growth of the market. For instance, the data published in the Journal, BMC Research Notes states that parasitic infections, particularly intestinal ones, are prevalent in 3.5 billion people, leading to over 450 million illnesses annually, particularly in developing countries, where parasites pose a significant public health issue.

The rising gynecologic infections accelerate the demand for metronidazole benzoate medications, leading to market expansion. For example, the data disclosed in the Journal, Microbiology Spectrum, indicates that vaginitis is a prevalent issue among women seeking primary care or gynecological services, with three common etiologies being trichomoniasis (TV), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC). The global prevalence of TV and BV is estimated at 5.3% and 26%, respectively.

The widespread availability of efficient medications and growing awareness of infections are driving growth in the metronidazole benzoate market. The industry is expanding as a result of rising healthcare costs in developing nations. It is anticipated that novel drug delivery techniques and improvements in pharmaceutical formulations would improve administration simplicity and efficacy. Trends toward self-medication and broad accessibility via Internet pharmacies are fueling metronidazole benzoate market growth. Profitable prospects are anticipated in the upcoming years owing to the accessibility of online drug purchases and pharmaceutical corporations' increasing investment in the R&D sector.

Report Coverage

This research report categorizes the global metronidazole benzoate market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global metronidazole benzoate market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global metronidazole benzoate market.

Driving Factors:

A broad range of applications of the metronidazole market:

Metronidazole is used to treat gastrointestinal issues caused by protozoa such as Trichomonas, Giardia, and Entamoeba. Additionally, it is used to treat anaerobic infections in horses and small animals. It is a unique kind of antibiotic that works effectively against anaerobic bacteria.  It is widely used and approved by the FDA to treat a wide range of infections, such as bacterial septicaemia, intestinal amebiasis, liver amebiasis, endocarditis, gynaecologic infections, intra-abdominal infections, lower respiratory tract infections, skin structure infections, bone and joint infections, and surgical prophylaxis. Metronidazole is applied topically to acne and intravaginally to bacterial vaginosis.

Technological advancements:

The growing demand for metronidazole benzoate in pharmaceutical formulations and its growing use in a variety of therapeutic areas are driving the market's expansion. The market is shifting as a result of the integration of AI and automation technologies, which enhance supply chain efficiency, industrial operations, and research and development procedures. Further, accurate medicine formulation and quality control have been rendered available by AI algorithms, and automation speeds up production and lowers expenses. These developments in technology assist in expanding the market, simplifying processes, and promoting innovation in the sector.

Restraining Factors

The repeated use of these drugs leads to antibiotic resistance, increasing consumption of metronidazole benzoate medications leads to side effects, rigorous regulatory guidelines, and the presence of alternative medications for the management of antibacterial and antiprotozoal infections may impede market growth.

Market Segmentation

The global metronidazole benzoate market share is classified into product type, applications, and distribution channel.

• The tablets segment held a significant share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global metronidazole benzoate market is categorized into capsules, suspensions, tablets, and others. Among these, the tablets segment held a significant share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is facilitated by effective treatment against protozoal and bacterial infections, availability of the novel drug delivery system such as immediate-release tablets and extended-release tablets, accurate dosing, affordable prices, ease of use, greater absorption, and prevention of the postoperative anaerobic bacterial infections associated with abdominal surgeries.

• The antibacterial segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the applications, the global metronidazole benzoate market is categorized into antiprotozoal, antibacterial, and others. Among these, the antibacterial segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the rising prevalence of antibacterial infections such as mouth and skin infections and protozoal infections, effective against anaerobic bacterial infections, and exerts potent therapeutic effects against gastrointestinal and vaginal infections.

• The hospitals segment dominated the global metronidazole benzoate market in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global metronidazole benzoate market is categorized as clinics, online pharmacies, hospitals, and others. Among these, the hospitals segment dominated the global metronidazole benzoate market in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe. The segment growth is attributed to the growing number of inpatient and outpatient services, availability of large bed services, sophisticated medical devices and treatment facilities in the hospital, provision of personalized medications and specialized healthcare services, and availability of skilled doctors and nurses, which gives better patient health outcomes.

Regional Segment Analysis of the Global Metronidazole Benzoate Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global metronidazole benzoate market over the predicted timeframe.

North America is anticipated to hold the largest share of the global metronidazole benzoate market over the predicted timeframe. This growth is accompanied by substantial healthcare expenses, widespread knowledge, and sophisticated medical facilities. The availability of several treatment choices and the existence of large pharmaceutical firms both support the market's expansion in this particular field. A major contributor to the market is the United States, which has a reliable healthcare system and a high rate of bacterial and protozoal diseases.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This growth is driven by an enormous patient base, increasing spending on healthcare, and greater accessibility to medical treatments. The incidence of bacterial and protozoal diseases is rising in nations like China, India, and Japan, which fosters the need for efficient therapies. The widespread availability of affordable healthcare remedies and rising awareness of these infections are fueling market expansion.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global metronidazole benzoate market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis AG
• Torrent Pharmaceuticals Ltd.
• Aurobindo Pharma Ltd.
• Sanofi
• Glenmark Pharmaceuticals Ltd.
• Mylan N.V.
• Lupin Limited
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Johnson and Johnson
• Cipla Limited
• Zydus Cadila
• Merck & Co., Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In November 2023, Kesin Parma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit dose formulations received the U.S. Food and Drug Administration (USFDA) for the LIKMEZ (metronidazole) oral suspension, 500mg/5 mL.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global metronidazole benzoate market based on the below-mentioned segments:

Global Metronidazole Benzoate Market, By Product Type

• Capsules
• Suspensions
• Tablets
• Others

Global Metronidazole Benzoate Market, By Applications

• Antiprotozoal
• Antibacterial
• Others

Global Metronidazole Benzoate Market, By Distribution Channel

• Clinics
• Online Pharmacies
• Hospitals
• Others

Global Metronidazole Benzoate Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa